P. Cáceres Guido, M. Pérez, A. Halac
Aug 12, 2019
Citations
0
Influential Citations
12
Citations
Journal
Pediatric Pulmonology
Abstract
Amikacin is commonly used in patients with pediatric cystic fibrosis (CF) for the treatment of pulmonary exacerbations. Amikacin efficacy is related to maximum plasma concentration/minimum inhibitory concentration (Cmax/MIC) ratio >8. Pharmacokinetic data in patients with pediatric CF are scarce. The aim of this study was to develop a population pharmacokinetic (PopPK) model describing amikacin disposition in patients with pediatric CF.